The selective enrichment of the SCFA-producing communities and the FFA2-Akt/PI3K pathway indicated that POS treatment has a potential therapeutic effect on T2DM by improving glucolipid metabolism. The gene discussed is FFAR2; the disease is type 2 diabetes mellitus.